Cryptococcosis Market Report 2025

The cryptococcosis market size has grown strongly in recent years. It will grow from $6.52 billion in 2024 to $7.14 billion in 2025 at a compound annual growth rate (CAGR) of 9.5%. The growth during the historic period can be attributed to the rising incidence of immunosuppressive conditions, advancements in antifungal therapies, an increase in organ transplant procedures, greater awareness of fungal infections, the development of amphotericin B formulations, the emergence of Cryptococcus gattii outbreaks, the expansion of healthcare infrastructure, and regulatory approvals for antifungal drugs.

The cryptococcosis market size is expected to see strong growth in the next few years. It will grow to $10.17 billion in 2029 at a compound annual growth rate (CAGR) of 9.2%. The growth during the forecast period can be attributed to the rising prevalence of human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) and immunosuppressive diseases, the increasing adoption of novel antifungal therapies, growing investments in research and development for antifungal drugs, the expansion of healthcare access in developing regions, the emergence of combination antifungal therapies, rising government initiatives for infectious disease control, and increasing awareness of cryptococcal infections. Major trends during this period include the development of next-generation antifungal drugs, AI-driven predictive analytics for infection outbreaks, nanotechnology-based drug delivery systems, wearable biosensors for early detection, blockchain for secure pharmaceutical supply chains, 3D bioprinting for fungal infection modeling, machine learning in antifungal drug discovery, and advancements in immunotherapy for cryptococcosis treatment.

The increasing occurrence of respiratory infections is expected to drive the growth of the cryptococcosis market. Respiratory infections, which impact the respiratory system including the nose, throat, airways, and lungs, can be caused by viruses, bacteria, or fungi. Air pollution is contributing to the rise in respiratory infections, as harmful pollutants such as smoke, dust, and chemicals damage lung function, making individuals more susceptible to diseases. A weakened immune system creates favorable conditions for opportunistic infections such as cryptococcosis to develop. This fungal infection, which primarily affects the lungs and central nervous system, poses significant risks for immunocompromised individuals. For example, in December 2024, the Australian Bureau of Statistics reported an increase in influenza-related deaths, with 951 deaths in 2024 compared to 427 in 2022. As a result, the growing incidence of respiratory infections is fueling the growth of the cryptococcosis market.

The increasing prevalence of human immunodeficiency virus (HIV) is also expected to drive the cryptococcosis market forward. HIV attacks the immune system, particularly targeting CD4 cells, making the body more vulnerable to infections and diseases. The rise in HIV cases is attributed to a lack of awareness and education regarding transmission and prevention, leading to risky behaviors, delayed diagnoses, and a higher rate of unintentional spread of the virus. As HIV weakens the immune system, individuals become more susceptible to opportunistic infections, including cryptococcosis. With the number of HIV cases increasing, the risk of cryptococcal infections rises, leading to greater demand for effective treatments and driving market growth. For instance, in October 2024, the UK Health Security Agency reported that HIV diagnoses increased by 51% in 2023, with 6,008 new cases compared to 3,975 in 2022. Therefore, the rising prevalence of HIV is contributing to the growth of the cryptococcosis market.

Leading companies in the cryptococcosis market are actively conducting clinical trials to improve the safety and effectiveness of antifungal treatments. These trials play a crucial role in assessing new therapies and enhancing treatment outcomes for patients suffering from severe fungal infections. For example, in August 2023, Matinas BioPharma Holdings Inc., a clinical-stage biopharmaceutical company based in the United States, reported promising results from its Phase II EnACT trial, which tested MAT2203 for the treatment of cryptococcal meningitis. MAT2203 is an oral lipid nanocrystal formulation of amphotericin B that targets fungal cell membranes, causing cell death. The trial demonstrated better survival rates among patients and a favorable safety profile, suggesting that MAT2203 could be a groundbreaking treatment for cryptococcosis, including cryptococcal meningitis.

Major players in the cryptococcosis market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Abbott Laboratories, Gilead Sciences Inc., Asahi Kasei Pharma Corporation, Viatris Inc., Astellas Pharma Inc., Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Cipla Limited, Dr. Reddy's Laboratories, Century Pharmaceuticals Ltd., Beijing Lunarsun Pharmaceutical Co. Ltd., PharmaCompass, Matinas Biopharma Holdings Inc., LGM Pharma, Atom Pharma, Brundavan Laboratories Pvt. Ltd., Zeon Health Industries, and Amar Healthcare.

North America was the largest region in the cryptococcosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cryptococcosis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cryptococcosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Cryptococcosis is a fungal infection caused by species of Cryptococcus, such as Cryptococcus neoformans and Cryptococcus gattii, which primarily affect the lungs and central nervous system (CNS). It primarily occurs in immunocompromised individuals, including those with human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS), organ transplant recipients, and patients undergoing immunosuppressive therapy. If untreated, this infection can lead to cryptococcal meningitis, a life-threatening condition.

The main treatment options for cryptococcosis include adjunctive therapies and antifungal drugs. Adjunctive therapies are additional treatments used alongside primary therapy to enhance effectiveness, improve patient outcomes, or manage side effects. Diagnostic techniques for cryptococcosis include culture methods, microscopic examination, and molecular techniques, which are used to diagnose various infections, including cerebral and pulmonary cryptococcosis. The primary end users of these treatments include clinics, home healthcare providers, hospitals, and research institutes.

The cryptococcosis market research report is one of a series of new reports that provides cryptococcosis market statistics, including cryptococcosis industry global market size, regional shares, competitors with a cryptococcosis market share, detailed cryptococcosis market segments, market trends and opportunities, and any further data you may need to thrive in the cryptococcosis industry. This cryptococcosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cryptococcosis market consists of revenues earned by entities by providing services such as diagnostic testing, antifungal treatment, hospital care, disease management, telemedicine consultations, research and development, clinical trials, patient monitoring, and epidemiological surveillance. The market value includes the value of related goods sold by the service provider or included within the service offering. The cryptococcosis market also includes sales of amphotericin B, flucytosine, fluconazole, and voriconazole. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.